GCM
GILD icon

Graham Capital Management’s Gilead Sciences GILD Stock Holding History

Graham Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-75,700
Closed -$7.14M – 128
2014
Q4 		$7.14M Hold
75,700
– – 0.3% 61
2014
Q3 		$8.06M Buy
75,700
+45,700
+152% +$4.47M 0.36% 63
2014
Q2 		$2.49M Buy
+30,000
New +$2.34M 0.07% 106

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Graham Capital Management's GILD Position: Q1 2025 in Review

Graham Capital Management sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 18,886 shares — an estimated $1.74M sold.

Graham Capital Management first reported a position in GILD in Q1 2014 and held it in 7 quarters. The position peaked at $6.85M in Q1 2015. 2,014 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

  • Graham Capital Management reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 18,886 Gilead Sciences shares in Q1 2025, an estimated $1.74M.
  • Graham Capital Management first reported a position in Gilead Sciences in Q1 2014 and held it in 7 quarters.
  • Graham Capital Management's Gilead Sciences position peaked at $6.85M in Q1 2015.
  • 2,014 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.